Kawaguchi, Hidetoshi http://orcid.org/0000-0002-0811-9335
Masuda, Norikazu
Nakayama, Takahiro
Aogi, Kenjiro
Anan, Keisei
Ito, Yoshinori
Ohtani, Shoichiro
Sato, Nobuaki
Saji, Shigehira
Takano, Toshimi
Tokunaga, Eriko
Nakamura, Seigo
Hasegawa, Yoshie
Hattori, Masaya
Fujisawa, Tomomi
Morita, Satoshi
Yamaguchi, Miki
Yamashita, Hiroko
Yamashita, Toshinari
Yamamoto, Yutaka
Yotsumoto, Daisuke
Toi, Masakazu
Ohno, Shinji
Funding for this research was provided by:
AstraZeneca
Article History
Received: 24 June 2019
Accepted: 28 November 2019
First Online: 6 December 2019
Compliance with ethical standards
:
: H. Kawaguchi received personal fees from Pfizer, Chugai, AstraZeneca, Eli Lilly, Eisai, Kyowa Kirin, Novartis, Taiho.Takeda. N. Masuda received grants, personal fees, and other from Chugai and Eisai, personal fees and other from AstraZeneca, Pfizer, Eli-Lilly, Takeda, Kyowa-Kirin, Novartis, and Daiichi Sankyo, and other from MSD. T. Nakayama received personal fees from AstraZeneca, Chugai, Novartis, Eli Lilly, Pfizer, Takeda. Taiho. K. Aogi received grants and personal fees from Eisai, personal fees from AstraZeneca, Daiichi Sankyo, Chugai, Taiho, Eli Lilly, Mochida, and Ono. K. Anan received personal fees from Pfizer, Chugai, AstraZeneca, Eisai and Novartis. Y. Ito received grants from Daiichi Sankyo, Chugai, Novartis, Parexel, EPS, MSD, AstraZeneca, Eli Lilly, Kyowa Hakko Kirin, Covance, Taiho, A2 Healthcare, QVIA services Japan, and Esai. S. Ohtani received personal fees from AstraZeneca, Pfizer, and Chugai. N. Sato received personal fees from AstraZeneca, Chugai, Eisai, and Taiho. S. Saji received grants and personal fees from Eisai, Chugai, AstraZeneca, Takeda, Novartis, Taiho, and Nihon Kayaku, personal fees from Kyowa Hakko Kirin, Pfizer, and Daiichi Sankyo, and grants from Ono. T. Takano received grants and personal fees from Daiichi Sankyo, Kyowa Hakko Kirin, and Eisai, grants from Ono, MSD, Merck Serono, Taiho, Novartis, and Chugai, and personal fees from Pfizer and Eli Lilly. E. Tokunaga received personal fees from Astra Zeneca and Pfizer. S. Nakamura received grants and personal fees from Novartis, Taiho and Takeda, grants from Pfizer; and personal fees from Nippon Kayaku and Shionogi. S. Morita received personal fees from Astra Zeneca. M. Yamaguchi received personal fees from Eli Lilly, Pfizer, Chugai Astra Zeneca, and Eisai. H. Yamashita received personal fees from Astra Zeneca, Takeda, Pfizer, Chugai Hitachi, Taiho, Daiichi Sankyo, Kyowa Hakko Kirin, Eli Lilly, Novartis, Nippon Kayaku, and Eisai. T. Yamashita received grants and other from Chugai, Nippon Kayaku, and Kyowa Hakko Kirin, and other from Eisai, Novartis Pharma, Taiho, AstraZeneca, and Pfizer. Dr. Yamamoto received personal fees from AstraZeneca, Pfizer, Nippon Kayaku, Kyowa Hakko Kirin, Chugai, Esai, Eli Lilly, Takeda, Sysmex, GE Health Care, and Daiich Sankyo. M. Toi received grants and personal fees from Taiho, Chugai, Takeda, Shimadzu, Eisai, Daiichi Sankyo, Pfizer, AstraZeneca, C&C Res Lab, and Kyowa-Hakko-Kirin, personal fees from Yakult, Konica-Minolta, Eli Lilly, MSD, Genomic Health, Novartis, Nihon Kayaku, and Ono, grants and non-financial support from Jpn Breast Cancer Research Group association, and non-financial support from Jpn Society Clinical Oncology, Jpn Surgical Society, Jpn Breast Cancer Society, Jpn Breast Cancer Research Group organization, Organisation for Oncology and Translational Research, and Kyoto Breast Cancer Research Network. S. Ohno received grants and personal fees from Eisai and Taiho, and personal fees from AstraZeneca, Chugai, Pfizer, Novartis, Nippon Kayaku, Kyowa Hakko Kirin, and Eli Lilly. Y. Hasegawa, Masaya Hattori, T. Fujisawa, and D. Yotsumoto have no financial or other relationships to declare.